Campylobacter fetus bacteremia in an immunocompromised patient: Case report and review of the literature

R. Monno, M. Rendina, G. Ceci, C. Rizzo, I. Luzzi, A. Francavilla, G. Rizzo, E. Ierardi

Research output: Contribution to journalArticle

Abstract

A 33-year-old woman underwent a liver transplantation and splenectomy in 1985 and had followed immunosuppressive therapy until 1995. Afterwards a non-Hodgkin lymphoma was diagnosed and chemotherapy was started. In January 2000, because of suspect transplantation rejection she was treated with steroid and immunosuppressive therapy. Fever occurred after two months and Cytomegalovirus (CMV) infection was diagnosed. Ganciclovir was started with clinical remission. In November 2000 fever recurred without clinical symptoms. Lymphoma recurrence was excluded and CMV was detected by PCR in several biological fluids. Blood cultures were positive for a bacterium that was identified as Campylobacter fetus. The patient was successfully treated with intravenous ciprofloxacin. For persistent CMV viremia therapy with gancyclovir was stopped and foscarnet was used (60mg/Kg/tid i.v. for two weeks). Bacteremia due to C. fetus is rare, occurring mainly in immunocompromised patients. In our patient the immunosuppressive therapy, chemotherapy for lymphoma and CMV infection had made the patient susceptible to bacteremia with this infrequently found bacterium. The clinical microbiologist should be aware of this infection in immunocompromised hosts.

Original languageEnglish
Pages (from-to)281-285
Number of pages5
JournalNew Microbiologica
Volume27
Issue number3
Publication statusPublished - Jul 2004

Fingerprint

Campylobacter fetus
Immunocompromised Host
Bacteremia
Immunosuppressive Agents
Ganciclovir
Cytomegalovirus Infections
Cytomegalovirus
Lymphoma
Fever
Foscarnet
Bacteria
Drug Therapy
Viremia
Graft Rejection
Splenectomy
Therapeutics
Ciprofloxacin
Liver Transplantation
Non-Hodgkin's Lymphoma
Steroids

Keywords

  • Bacteremia
  • C. fetus
  • CMV infection
  • Immunocompromised host

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Monno, R., Rendina, M., Ceci, G., Rizzo, C., Luzzi, I., Francavilla, A., ... Ierardi, E. (2004). Campylobacter fetus bacteremia in an immunocompromised patient: Case report and review of the literature. New Microbiologica, 27(3), 281-285.

Campylobacter fetus bacteremia in an immunocompromised patient : Case report and review of the literature. / Monno, R.; Rendina, M.; Ceci, G.; Rizzo, C.; Luzzi, I.; Francavilla, A.; Rizzo, G.; Ierardi, E.

In: New Microbiologica, Vol. 27, No. 3, 07.2004, p. 281-285.

Research output: Contribution to journalArticle

Monno, R, Rendina, M, Ceci, G, Rizzo, C, Luzzi, I, Francavilla, A, Rizzo, G & Ierardi, E 2004, 'Campylobacter fetus bacteremia in an immunocompromised patient: Case report and review of the literature', New Microbiologica, vol. 27, no. 3, pp. 281-285.
Monno R, Rendina M, Ceci G, Rizzo C, Luzzi I, Francavilla A et al. Campylobacter fetus bacteremia in an immunocompromised patient: Case report and review of the literature. New Microbiologica. 2004 Jul;27(3):281-285.
Monno, R. ; Rendina, M. ; Ceci, G. ; Rizzo, C. ; Luzzi, I. ; Francavilla, A. ; Rizzo, G. ; Ierardi, E. / Campylobacter fetus bacteremia in an immunocompromised patient : Case report and review of the literature. In: New Microbiologica. 2004 ; Vol. 27, No. 3. pp. 281-285.
@article{4de4ff5831e342d5b7a503afb90f785d,
title = "Campylobacter fetus bacteremia in an immunocompromised patient: Case report and review of the literature",
abstract = "A 33-year-old woman underwent a liver transplantation and splenectomy in 1985 and had followed immunosuppressive therapy until 1995. Afterwards a non-Hodgkin lymphoma was diagnosed and chemotherapy was started. In January 2000, because of suspect transplantation rejection she was treated with steroid and immunosuppressive therapy. Fever occurred after two months and Cytomegalovirus (CMV) infection was diagnosed. Ganciclovir was started with clinical remission. In November 2000 fever recurred without clinical symptoms. Lymphoma recurrence was excluded and CMV was detected by PCR in several biological fluids. Blood cultures were positive for a bacterium that was identified as Campylobacter fetus. The patient was successfully treated with intravenous ciprofloxacin. For persistent CMV viremia therapy with gancyclovir was stopped and foscarnet was used (60mg/Kg/tid i.v. for two weeks). Bacteremia due to C. fetus is rare, occurring mainly in immunocompromised patients. In our patient the immunosuppressive therapy, chemotherapy for lymphoma and CMV infection had made the patient susceptible to bacteremia with this infrequently found bacterium. The clinical microbiologist should be aware of this infection in immunocompromised hosts.",
keywords = "Bacteremia, C. fetus, CMV infection, Immunocompromised host",
author = "R. Monno and M. Rendina and G. Ceci and C. Rizzo and I. Luzzi and A. Francavilla and G. Rizzo and E. Ierardi",
year = "2004",
month = "7",
language = "English",
volume = "27",
pages = "281--285",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "3",

}

TY - JOUR

T1 - Campylobacter fetus bacteremia in an immunocompromised patient

T2 - Case report and review of the literature

AU - Monno, R.

AU - Rendina, M.

AU - Ceci, G.

AU - Rizzo, C.

AU - Luzzi, I.

AU - Francavilla, A.

AU - Rizzo, G.

AU - Ierardi, E.

PY - 2004/7

Y1 - 2004/7

N2 - A 33-year-old woman underwent a liver transplantation and splenectomy in 1985 and had followed immunosuppressive therapy until 1995. Afterwards a non-Hodgkin lymphoma was diagnosed and chemotherapy was started. In January 2000, because of suspect transplantation rejection she was treated with steroid and immunosuppressive therapy. Fever occurred after two months and Cytomegalovirus (CMV) infection was diagnosed. Ganciclovir was started with clinical remission. In November 2000 fever recurred without clinical symptoms. Lymphoma recurrence was excluded and CMV was detected by PCR in several biological fluids. Blood cultures were positive for a bacterium that was identified as Campylobacter fetus. The patient was successfully treated with intravenous ciprofloxacin. For persistent CMV viremia therapy with gancyclovir was stopped and foscarnet was used (60mg/Kg/tid i.v. for two weeks). Bacteremia due to C. fetus is rare, occurring mainly in immunocompromised patients. In our patient the immunosuppressive therapy, chemotherapy for lymphoma and CMV infection had made the patient susceptible to bacteremia with this infrequently found bacterium. The clinical microbiologist should be aware of this infection in immunocompromised hosts.

AB - A 33-year-old woman underwent a liver transplantation and splenectomy in 1985 and had followed immunosuppressive therapy until 1995. Afterwards a non-Hodgkin lymphoma was diagnosed and chemotherapy was started. In January 2000, because of suspect transplantation rejection she was treated with steroid and immunosuppressive therapy. Fever occurred after two months and Cytomegalovirus (CMV) infection was diagnosed. Ganciclovir was started with clinical remission. In November 2000 fever recurred without clinical symptoms. Lymphoma recurrence was excluded and CMV was detected by PCR in several biological fluids. Blood cultures were positive for a bacterium that was identified as Campylobacter fetus. The patient was successfully treated with intravenous ciprofloxacin. For persistent CMV viremia therapy with gancyclovir was stopped and foscarnet was used (60mg/Kg/tid i.v. for two weeks). Bacteremia due to C. fetus is rare, occurring mainly in immunocompromised patients. In our patient the immunosuppressive therapy, chemotherapy for lymphoma and CMV infection had made the patient susceptible to bacteremia with this infrequently found bacterium. The clinical microbiologist should be aware of this infection in immunocompromised hosts.

KW - Bacteremia

KW - C. fetus

KW - CMV infection

KW - Immunocompromised host

UR - http://www.scopus.com/inward/record.url?scp=11444256363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444256363&partnerID=8YFLogxK

M3 - Article

C2 - 15460531

AN - SCOPUS:11444256363

VL - 27

SP - 281

EP - 285

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 3

ER -